Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 2 Metastatic Non-Squamous Non-Small Cell Lung Cancer 1 Melanoma 1 Lung Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Advanced or Metastatic Solid Malignancies 1 Advanced Malignancies 1 Adenocarcinoma 1

Interventions

pembrolizumab 137 Nivolumab 116 Ipilimumab 68 Cyclophosphamide 33 Specimen Handling 31 Magnetic Resonance Spectroscopy 28 trametinib 23 binimetinib 22 fludarabine 21 Interleukin-2 20 dabrafenib 19 relatlimab 17 encorafenib 17 Biopsy 17 CTLA-4 Antigen 16 cemiplimab 15 atezolizumab 15 aldesleukin 15 Radiosurgery 15 fludarabine phosphate 14 Opdualag 14 Radiotherapy 11 lenvatinib 10 Blood Specimen Collection 10 lifileucel 9 Paclitaxel 8 Cisplatin 8 Bevacizumab 8 spartalizumab 7 cobimetinib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × sitravatinib × 1 year × Clear all

NCT05542342 2026-06-01

SITISVEAL

Grupo Español Multidisciplinar de Melanoma

Phase 2 Completed

16 enrolled 14 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡